
Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.
In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.
In the first quarter of 2025, a variety of advancements in the field of






